Developer docs
API playgroundTry for free, no card

Search company profiles

NeuraLight

Full company profile

uuid0000jkd

Namestring
NeuraLight
Legal namestring
Neuralight, Inc.
Websiteurl
neuralight.ai
Company typeenum
Private
Founded yearint
2021
Descriptiontext

NeuraLight is a private, venture-backed digital health company founded in 2021 and headquartered in Tel Aviv with U.S. offices in Austin and New York. The company develops a software-based platform that uses proprietary computer vision and machine learning to extract objective neurological biomarkers from eye movements captured via standard webcams and tablets, with a primary focus on neurodegenerative disease assessment in clinical trial settings.

The core product is a three-stage workflow — standardized visual assessment completed in minutes, AI-driven analysis of task performance, and extraction of multiple quantitative biomarkers per session. Its lead biomarker, ASH (Amplitude of Saccadic Hypometria), provides a direct functional readout of basal ganglia circuitry and has been clinically validated across multiple independent cohorts (P-value <0.0001), with the company reporting 10x greater sensitivity than the MDS-UPDRS gold standard in tracking Parkinson's disease progression. The platform is being evaluated across Parkinson's, ALS, MS, PSP, MSA, and Huntington's disease, supported by a portfolio of 12+ peer-reviewed publications and multicenter clinical studies including PALOMA and PARATROOPER.

NeuraLight operates a B2B SaaS model, licensing the platform through direct enterprise sales to pharmaceutical and biotech companies conducting clinical trials, with pricing negotiated per trial or partnership. Customers and partners include Teitur Trophics, Kariya Pharmaceuticals, NeuroSense Therapeutics, and CHDI Foundation. The company is led by co-founders Edmund Ben Ami (CEO) and Gil Shklarski (Scientific Co-founder), with Nobel laureate Prof. Thomas Südhof as Scientific Co-founder and Prof. Olivier Rascol — co-creator of the MDS-UPDRS — heading the Scientific Advisory Board. Total disclosed funding is $30.5M across a $5.5M seed (Oct 2021) and a $25M Series A led by Koch Disruptive Technologies (May 2022).

Short descriptiontext

NeuraLight develops a software-based AI platform that uses computer vision to extract objective neurological biomarkers from eye-movement video, sold as a B2B SaaS tool to pharmaceutical and biotech companies running clinical trials in Parkinson's, ALS, MS, and Huntington's disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital neurological biomarkers, clinical trial endpoints, oculometric measurement software, neurodegenerative disease research, AI brain function analysis
Industry4 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHDAAAJAE
Real-Time Vision at the Edge (on-device CV/video)
SECONDARYHLAKAKAH
Neuro-Ophthalmology
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
Clinical Trial Biomarker Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biomarker Platform SaaS Subscription
TypeSubscription Recurring
Description

NeuraLight licenses its precision brain function biomarker platform to pharmaceutical and biotech companies for use in clinical trials. The platform is deployed as a software-as-a-service solution integrated into drug trial protocols to provide quantitative assessment of disease-relevant neural pathway function.

trib.al
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

NeuraLight develops a software-based platform that uses proprietary computer vision and machine learning to extract precision biomarkers of brain function from eye movements captured via standard webcams and tablets. The platform delivers standardized visual assessments, AI-driven analysis, and multiple quantitative oculometric biomarkers per session in minutes. It is licensed to pharmaceutical and biotech companies as a SaaS solution for use as objective endpoints in clinical trials for Parkinson's, ALS, MS, Huntington's, PSP, and MSA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 10x greater sensitivity than MDS-UPDRS in tracking Parkinson's disease progression
+3 more records
Product overview1 text field

NeuraLight offers a unified software-based platform for precision brain function measurement through eye movement analysis. The core NeuraLight Platform uses computer vision and deep learning to extract objective biomarkers from video assessments, with products including the ASH (Amplitude of Saccadic Hypometria) biomarker for Parkinson's disease tracking and the Precision Brain Function Biomarker Platform deployed across multiple neurodegenerative indications (Parkinson's, ALS, MS, PSP, MSA, Huntington's disease). The platform delivers three-stage workflow: Assessment (standardized visual tasks), Analysis (proprietary algorithms), and Results (quantitative biomarker outputs) with 10x sensitivity improvement over traditional clinical scales.

Product and service4 records
1NeuraLight Platform
2ASH (Amplitude of Saccadic Hypometria) Biomarker
3Precision Brain Function Biomarker Platform
4Neuroprogression Biomarker Readouts
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-14
Description

NeuraLight and Kariya Pharmaceuticals partnered to integrate NeuraLight's precision biomarker platform into Kariya's Phase II clinical trial program for KP405, a first-in-class brain-penetrant dual GLP-1/GIP receptor agonist in development for Parkinson's and Alzheimer's disease. NeuraLight's platform will be used to quantify the neuroprotective effect of KP405 and provide objective, quantitative assessment of brain function. KP405 is engineered to cross the blood-brain barrier and reduce neuroinflammation and protect neurons.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-21
Description

NeuraLight and Teitur Trophics entered a collaboration granting Teitur Trophics access to NeuraLight's precision brain function biomarker platform for use in Teitur Trophics' upcoming Phase I clinical trial of TT-P34, a novel neuroprotective compound in development for Parkinson's disease. NeuraLight's platform will provide quantitative assessment of disease-relevant neural pathway function to support evaluation of TT-P34's potential as a disease-modifying therapy. TT-P34 is a subcutaneously administered cyclic peptide designed to reactivate CREB signaling and improve lysosomal and mitochondrial function.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-09
Description

NeuraLight and CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to developing therapeutics for Huntington's disease, announced a collaboration to develop sensitive precision eye movement biomarkers to support Huntington's disease clinical trials. A collaborative study was conducted at the 2025 HDSA Annual Convention in Indianapolis, with NeuraLight building one of the largest eye movement datasets in HD to support the development of trial-ready biomarkers.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-07-28
Description

NeuraLight and NeuroSense Therapeutics partnered to advance the development of objective biomarkers for monitoring ALS disease progression. The collaboration aimed to demonstrate that oculometrics provide an objective, reliable, and replicable measure of ALS progression, with goals to improve patient stratification, trial power, and reduce sample sizes and trial duration for ALS drug development programs including PrimeC.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eye-tracking-based cognitive assessment platform for early detection of CNS disorders including Alzheimer's. Closest peer in oculometric/cognitive biomarker modality for neurodegenerative trials.

TypeDirect peer
Description

Digital neuro biomarker platform using smartphone/AR-based assessments to predict and track cognitive decline, including Alzheimer's and Parkinson's. Most direct peer in digital CNS biomarker SaaS for pharma clinical trials.

TypeDirect peer
Description

Provides a multi-modal digital biomarker platform (EEG, voice, cognition) for CNS clinical trials in indications such as Alzheimer's and depression. Directly competes for the same pharma trial endpoint budget.

TypeDirect peer
Description

Digital biomarker company specializing in wearable/sensor-derived endpoints for neurological and rare disease clinical trials. Comparable B2B SaaS model targeting pharma/biotech trial sponsors.

TypeDirect peer
Description

Provider of computerized cognitive assessments (e.g., CANTAB) widely used as endpoints in CNS clinical trials across pharma and academic research. Overlapping customer base and use cases with NeuraLight in neuro trials.

6IXICO
TypeDirect peer
Description

Imaging and digital biomarker analytics for neuroscience clinical trials, particularly in Huntington's, Alzheimer's, and other neurodegenerative indications. Competes for the same trial endpoint and patient stratification spend.

TypeBroad incumbent
Description

Large clinical trial technology company formed from ERT and Bioclinica, offering eCOA, imaging, and digital endpoint solutions across therapeutic areas. Broad incumbent competing for digital endpoint wallet share in CNS trials.

TypeBroad incumbent
Description

Leading clinical trial SaaS platform owned by Dassault Systèmes, increasingly adding sensor- and digital biomarker-derived endpoints. Broad incumbent competing for end-to-end trial data capture in neuro programs.

TypeBroad incumbent
Description

Internal digital health/biomarker arm of major neuroscience-focused pharma Biogen. Represents the in-house alternative that could displace external vendors like NeuraLight on pivotal neuro trials.

TypeOthers
Description

Provider of tau PET imaging biomarkers used as endpoints in Alzheimer's clinical trials. Adjacent enabling peer in CNS trial endpoints, illustrating an alternative (imaging-based) modality competing for the same trial endpoints.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuraLight

Clinical Trial Biomarker Softwareneuralight.ai

NeuraLight develops a software-based AI platform that uses computer vision to extract objective neurological biomarkers from eye-movement video, sold as a B2B SaaS tool to pharmaceutical and biotech companies running clinical trials in Parkinson's, ALS, MS, and Huntington's disease.

What NeuraLight does

NeuraLight is a private, venture-backed digital health company founded in 2021 and headquartered in Tel Aviv with U.S. offices in Austin and New York. The company develops a software-based platform that uses proprietary computer vision and machine learning to extract objective neurological biomarkers from eye movements captured via standard webcams and tablets, with a primary focus on neurodegenerative disease assessment in clinical trial settings.

The core product is a three-stage workflow — standardized visual assessment completed in minutes, AI-driven analysis of task performance, and extraction of multiple quantitative biomarkers per session. Its lead biomarker, ASH (Amplitude of Saccadic Hypometria), provides a direct functional readout of basal ganglia circuitry and has been clinically validated across multiple independent cohorts (P-value <0.0001), with the company reporting 10x greater sensitivity than the MDS-UPDRS gold standard in tracking Parkinson's disease progression. The platform is being evaluated across Parkinson's, ALS, MS, PSP, MSA, and Huntington's disease, supported by a portfolio of 12+ peer-reviewed publications and multicenter clinical studies including PALOMA and PARATROOPER.

NeuraLight operates a B2B SaaS model, licensing the platform through direct enterprise sales to pharmaceutical and biotech companies conducting clinical trials, with pricing negotiated per trial or partnership. Customers and partners include Teitur Trophics, Kariya Pharmaceuticals, NeuroSense Therapeutics, and CHDI Foundation. The company is led by co-founders Edmund Ben Ami (CEO) and Gil Shklarski (Scientific Co-founder), with Nobel laureate Prof. Thomas Südhof as Scientific Co-founder and Prof. Olivier Rascol — co-creator of the MDS-UPDRS — heading the Scientific Advisory Board. Total disclosed funding is $30.5M across a $5.5M seed (Oct 2021) and a $25M Series A led by Koch Disruptive Technologies (May 2022).

NeuraLight firmographics

Firmographics
Name
NeuraLight
Legal name
Neuralight, Inc.
Website
https://neuralight.ai
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuraLight develops a software-based AI platform that uses computer vision to extract objective neurological biomarkers from eye-movement video, sold as a B2B SaaS tool to pharmaceutical and biotech companies running clinical trials in Parkinson's, ALS, MS, and Huntington's disease.
Ownership category
akta.pro rank

NeuraLight industry classification

Industry
Product category
Clinical Trial Biomarker Software
NAICS
Computer Systems Design and Related Services (54151), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHDAAAJAE
Real-Time Vision at the Edge (on-device CV/video)
SECONDARYHLAKAKAH
Neuro-Ophthalmology

Keywords

  • Digital neurological biomarkers
  • Clinical trial endpoints
  • Oculometric measurement software
  • Neurodegenerative disease research
  • AI brain function analysis

Where NeuraLight is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

NeuraLight business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Biomarker Platform SaaS Subscription: NeuraLight licenses its precision brain function biomarker platform to pharmaceutical and biotech companies for use in clinical trials. The platform is deployed as a software-as-a-service solution integrated into drug trial protocols to provide quantitative assessment of disease-relevant neural pathway function.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

NeuraLight product offering

Product offering

Core offering

NeuraLight develops a software-based platform that uses proprietary computer vision and machine learning to extract precision biomarkers of brain function from eye movements captured via standard webcams and tablets. The platform delivers standardized visual assessments, AI-driven analysis, and multiple quantitative oculometric biomarkers per session in minutes. It is licensed to pharmaceutical and biotech companies as a SaaS solution for use as objective endpoints in clinical trials for Parkinson's, ALS, MS, Huntington's, PSP, and MSA.

Product overview

NeuraLight offers a unified software-based platform for precision brain function measurement through eye movement analysis. The core NeuraLight Platform uses computer vision and deep learning to extract objective biomarkers from video assessments, with products including the ASH (Amplitude of Saccadic Hypometria) biomarker for Parkinson's disease tracking and the Precision Brain Function Biomarker Platform deployed across multiple neurodegenerative indications (Parkinson's, ALS, MS, PSP, MSA, Huntington's disease). The platform delivers three-stage workflow: Assessment (standardized visual tasks), Analysis (proprietary algorithms), and Results (quantitative biomarker outputs) with 10x sensitivity improvement over traditional clinical scales.

Differentiator

Problem solved

Functional benefit

Products and services

  • NeuraLight Platform
  • ASH (Amplitude of Saccadic Hypometria) Biomarker
  • Precision Brain Function Biomarker Platform
  • Neuroprogression Biomarker Readouts

Quantifiable outcome

  • 10x greater sensitivity than MDS-UPDRS in tracking Parkinson's disease progression
  • +3 more outcomes

Companies that use NeuraLight

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

NeuraLight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

NeuraLight partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Kariya PharmaceuticalscoreStrategic or Co-development Partner · 14 May 2026NeuraLight and Kariya Pharmaceuticals partnered to integrate NeuraLight's precision biomarker platform into Kariya's Phase II clinical trial program for KP405, a first-in-class brain-penetrant dual GLP-1/GIP receptor agonist in development for Parkinson's and Alzheimer's disease. NeuraLight's platform will be used to quantify the neuroprotective effect of KP405 and provide objective, quantitative assessment of brain function. KP405 is engineered to cross the blood-brain barrier and reduce neuroinflammation and protect neurons.
  • Teitur Trophics ApScoreStrategic or Co-development Partner · 21 January 2026NeuraLight and Teitur Trophics entered a collaboration granting Teitur Trophics access to NeuraLight's precision brain function biomarker platform for use in Teitur Trophics' upcoming Phase I clinical trial of TT-P34, a novel neuroprotective compound in development for Parkinson's disease. NeuraLight's platform will provide quantitative assessment of disease-relevant neural pathway function to support evaluation of TT-P34's potential as a disease-modifying therapy. TT-P34 is a subcutaneously administered cyclic peptide designed to reactivate CREB signaling and improve lysosomal and mitochondrial function.
  • CHDI FoundationcoreStrategic or Co-development Partner · 9 September 2025NeuraLight and CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to developing therapeutics for Huntington's disease, announced a collaboration to develop sensitive precision eye movement biomarkers to support Huntington's disease clinical trials. A collaborative study was conducted at the 2025 HDSA Annual Convention in Indianapolis, with NeuraLight building one of the largest eye movement datasets in HD to support the development of trial-ready biomarkers.
  • NeuroSense TherapeuticsminorStrategic or Co-development Partner · 28 July 2022NeuraLight and NeuroSense Therapeutics partnered to advance the development of objective biomarkers for monitoring ALS disease progression. The collaboration aimed to demonstrate that oculometrics provide an objective, reliable, and replicable measure of ALS progression, with goals to improve patient stratification, trial power, and reduce sample sizes and trial duration for ALS drug development programs including PrimeC.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

NeuraLight competitors and assessment

Company assessment

Direct peers

  • ViewMind: Eye-tracking-based cognitive assessment platform for early detection of CNS disorders including Alzheimer's. Closest peer in oculometric/cognitive biomarker modality for neurodegenerative trials.
  • Altoida: Digital neuro biomarker platform using smartphone/AR-based assessments to predict and track cognitive decline, including Alzheimer's and Parkinson's. Most direct peer in digital CNS biomarker SaaS for pharma clinical trials.
  • Cumulus Neuroscience: Provides a multi-modal digital biomarker platform (EEG, voice, cognition) for CNS clinical trials in indications such as Alzheimer's and depression. Directly competes for the same pharma trial endpoint budget.
  • VivoSense: Digital biomarker company specializing in wearable/sensor-derived endpoints for neurological and rare disease clinical trials. Comparable B2B SaaS model targeting pharma/biotech trial sponsors.
  • Cambridge Cognition: Provider of computerized cognitive assessments (e.g., CANTAB) widely used as endpoints in CNS clinical trials across pharma and academic research. Overlapping customer base and use cases with NeuraLight in neuro trials.
  • IXICO: Imaging and digital biomarker analytics for neuroscience clinical trials, particularly in Huntington's, Alzheimer's, and other neurodegenerative indications. Competes for the same trial endpoint and patient stratification spend.

Broad incumbents

  • Clario: Large clinical trial technology company formed from ERT and Bioclinica, offering eCOA, imaging, and digital endpoint solutions across therapeutic areas. Broad incumbent competing for digital endpoint wallet share in CNS trials.
  • Medidata (Dassault Systèmes): Leading clinical trial SaaS platform owned by Dassault Systèmes, increasingly adding sensor- and digital biomarker-derived endpoints. Broad incumbent competing for end-to-end trial data capture in neuro programs.
  • Biogen Digital Health: Internal digital health/biomarker arm of major neuroscience-focused pharma Biogen. Represents the in-house alternative that could displace external vendors like NeuraLight on pivotal neuro trials.

Others

  • Cerveau Technologies: Provider of tau PET imaging biomarkers used as endpoints in Alzheimer's clinical trials. Adjacent enabling peer in CNS trial endpoints, illustrating an alternative (imaging-based) modality competing for the same trial endpoints.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

NeuraLight social profiles

Digital presence

NeuraLight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuraLight leadership team

Management profile

Number of profiles

Profiles18 records

NeuraLight funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuraLight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuraLight

What does NeuraLight do?

NeuraLight develops a software-based platform that uses proprietary computer vision and machine learning to extract precision biomarkers of brain function from eye movements captured via standard webcams and tablets. The platform delivers standardized visual assessments, AI-driven analysis, and multiple quantitative oculometric biomarkers per session in minutes. It is licensed to pharmaceutical and biotech companies as a SaaS solution for use as objective endpoints in clinical trials for Parkinson's, ALS, MS, Huntington's, PSP, and MSA.

Is NeuraLight a public or private company?

NeuraLight is a private company. It is classified as venture growth investor backed and is currently operating.

When was NeuraLight founded?

NeuraLight was founded in 2021. It employs 11 to 50 people.

Where is NeuraLight based?

NeuraLight is headquartered in Tel Aviv, Israel, in the Middle East region.

How does NeuraLight make money?

One revenue line is on record: biomarker Platform SaaS Subscription.

Who are NeuraLight's main competitors?

Direct peers on record are ViewMind, Altoida, Cumulus Neuroscience, VivoSense, Cambridge Cognition and IXICO. Broad incumbents are Clario, Medidata (Dassault Systèmes) and Biogen Digital Health. Cerveau Technologies is listed as an others.

Does NeuraLight have an API?

No public API is recorded for NeuraLight.

What industry is NeuraLight in?

NeuraLight's product category is Clinical Trial Biomarker Software. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 54151 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyTracking eye movement to fight Parkinson’sMission Therapeutics partnered with NeuraLight to use eye-movement tracking in a multi-country Parkinson's trial for its drug MTX325, which blocks USP30 to restore mitophagy. The Phase Ib trial spans the UK, Europe, and Australia, aiming to detect early functional changes missed by clinical scales.Longevity.TechnologyMission Therapeutics, NeuraLight partner on Parkinson’s biomarkersMission Therapeutics and NeuraLight partnered to deploy NeuraLight's eye-movement-derived brain function biomarkers in the multinational MTX325 trial for Parkinson's disease. The biomarkers aim to quantify neural pathway function and detect subtle changes missed by conventional scales. MTX325, a USP30 inhibitor, is advancing into a Phase Ib proof-of-mechanism study.BioSpaceMission Therapeutics and NeuraLight Partner to Bring Precision Brain Function Biomarkers to a Global Parkinson’s Disease Clinical TrialMission Therapeutics and NeuraLight partnered to use NeuraLight's brain function biomarkers in Mission's multinational trial of MTX325 for Parkinson's disease. MTX325 is a USP30 inhibitor restoring mitophagy, with preclinical data showing neuroprotection. The trial spans clinical sites in the UK, Europe, and Australia.FinancialContent Business PageMission Therapeutics and NeuraLight Partner to Bring Precision Brain Function Biomarkers to a Global Parkinson's Disease Clinical TrialMission Therapeutics and NeuraLight announced a partnership to use NeuraLight's eye-movement-based brain function biomarkers across Mission's multinational trial of MTX325 in Parkinson's disease. Sites span the UK, Europe and Australia. MTX325 is a first-in-class, brain-penetrant USP30 inhibitor designed to restore mitophagy, with preclinical data published in Nature. The company is advancing into a Phase Ib proof-of-mechanism study.Joplin GlobeLandmark International Brain Health Initiative Deploys NeuraLight's Biomarkers to Quantify Change in Brain Function | National Business | joplinglobe.comNeuraLight announced that its precision brain function biomarkers will be deployed in the Healthy Brain Ageing (HeBA) study, a major European initiative designed to detect early changes in brain function up to a decade before symptoms appear. This collaboration aims to provide objective, quantifiable data on brain health across the aging population to support research into neurodegenerative diseases. The initiative represents a strategic partnership to advance diagnostic capabilities in the field of healthy brain aging.FinancialContent Business PageLandmark International Brain Health Initiative Deploys NeuraLight's Biomarkers to Quantify Change in Brain FunctionNeuraLight announced the deployment of its precision biomarkers within the Healthy Brain Ageing (HeBA) initiative, a population-scale study spanning Germany, Austria, Spain, and Luxembourg. The program involves nearly 13,000 adults aged 50 to 80 and is supported by The Michael J. Fox Foundation to detect early signs of neurodegenerative diseases like Parkinson's. This integration aims to provide sensitive, quantitative measures of brain function that complement existing clinical assessments.MorningstarClinical Trial Results Show NeuraLight Biomarkers Predict Functional Decline in People With Parkinson’s DiseaseNeuraLight announced trial data from a multicenter study of 250 adults in the US and Europe, showing its biomarkers predict functional decline in Parkinson's disease. The biomarkers were more sensitive than the gold-standard assessment in capturing changes in daily function.Business Wire BlogNeuraLight Wins Fast Company’s World Changing Ideas Award for Its Innovation in Brain Function MeasurementNeuraLight, a healthtech company specializing in precision brain function biomarkers, has won Fast Company's 2026 World Changing Ideas Award in the Future of Health category, recognizing its AI-powered platform that uses eye movements to measure and quantify brain function. The award follows a series of clinical and commercial milestones, including partnerships with pharmaceutical companies for GLP-1 therapeutics programs and the addition of Nobel laureate Thomas Südhof as Scientific Co-Founder. The recognition positions NeuraLight alongside previous award winners like WHOOP and Dexcom, which similarly redefined how health is measured in their respective domains.BioSpaceNeuraLight Biomarkers Reveal What Parkinson’s Gold-Standard Measurement Scale Misses in a Study Led by the Scale’s Own DevelopersNeuraLight announced a peer-reviewed study of 280 Parkinson's patients across five countries, finding its biomarkers detected disease progression where the MDS-UPDRS gold standard did not. The biomarkers, including ASH, showed significant deterioration (P<0.0001) across sites, while MDS-UPDRS scores were not significant. The findings aim to improve sensitivity in Parkinson's disease-modifying trials.Business Wire BlogNeuraLight Biomarkers Reveal What Parkinson's Gold-Standard Measurement Scale Misses in a Study Led by the Scale's Own DevelopersNeuraLight announced a peer-reviewed study demonstrating that its precision biomarkers outperformed the MDS-UPDRS in detecting Parkinson's disease progression across 280 patients in five countries. Led by developers of the MDS-UPDRS, the research indicates that NeuraLight's objective eye-tracking measures provide consistent signals where clinician scoring fails, potentially improving clinical trial efficiency.